Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Cabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria i...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Daniel J., Hessel, Colin, Halabi, Susan, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, Morris, Michael J., Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853096/
https://www.ncbi.nlm.nih.gov/pubmed/31399500
http://dx.doi.org/10.1634/theoncologist.2019-0316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853096/
https://www.ncbi.nlm.nih.gov/pubmed/31399500
http://dx.doi.org/10.1634/theoncologist.2019-0316

Ejemplares similares